Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis

10.1182/blood-2009-02-203075

10.1212/WNL.0b013e3181c97ed3

10.1136/jnnp-2011-300826

10.1200/JCO.2002.06.119

10.1016/S0140-6736(12)61768-1

10.1002/14651858.CD008078.pub2

10.1016/S0140-6736(12)61769-3

European Medicine Agency. Lemtrada: summary of product characteristics; [cited 2018 Mar 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf

10.1212/WNL.0b013e31827b5927

10.1177/1352458514549398

10.1212/NXI.0000000000000228

10.1016/j.msard.2017.09.028

Havla J, 2016, Dtsch Arztebl Int, 113, 879

10.1212/WNL.0b013e31824e8ee7

10.1056/NEJMoa0802670

10.1016/j.cmi.2018.02.003

10.2147/TCRM.S143509

10.1016/j.msard.2017.03.001

10.1177/1352458516688350

10.1016/j.msard.2017.12.009

10.1001/jamaneurol.2016.0146

10.1177/1352458517694431

10.1038/nrneurol.2016.21

10.1016/j.jocn.2017.08.051

10.1001/jamaneurol.2016.0259

Oreja-Guevara C Safety issues in multiple sclerosis patients treated with alemtuzumab in real world. Poster session presented at European Committee for Treatment and Research in Multiple Sclerosis - ECTRIMS; 2017 Oct 25-28; Paris.

10.26226/morressier.59a3e8b7d462b8028d895644

10.15226/sojmid/6/1/00189

10.26226/morressier.59a3e8b7d462b8028d89564e

10.1186/s12883-017-0848-8

10.3390/ijms160714669

Canham L Mortality from listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting multiple sclerosis. Poster session presented at European Committee for Treatment and Research in Multiple Sclerosis - ECTRIMS; 2017 Oct 25-28; Paris.

10.1086/340041

10.1093/infdis/142.3.338

10.1093/infdis/156.2.280

10.1111/j.1399-3062.2010.00547.x

10.1002/ajh.21152

10.1056/NEJMcp013211

10.1111/j.1600-6143.2005.00822.x

10.3109/10428194.2012.659735

10.1086/508173

10.1097/00007890-198309000-00007

Bowen EF, 1996, AIDS, 10, S37

10.1016/S1470-2045(11)70242-X

10.1002/jmv.22013

Laurenti L, 2004, Haematologica, 89, 1248

10.1002/hon.2453

Jung Henson L, 2015, Neurology, 84

Food and Drug Administration. Lemtrada: summary of product characteristics; [cited 2018 Mar 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf

10.3816/CLM.2006.n.049

10.1016/j.micinf.2007.05.011

10.1086/428575

European Centre for Disease Prevention and Control. Annual epidemiological report 2016 – listeriosis. [Internet]. Stockholm: ECDC; 2016 [cited 2018 May 20]. Available from: http://ecdc.europa.eu/en/healthtopics/listeriosis/Pages/Annual­epidemiological­report­2016.aspx

10.1093/cid/cir902

10.1517/14656566.5.8.1727

10.1016/S0163-4453(96)92929-1

Selmaj KW, Habek M, Bass AD, et al. Efficacy and safety of alemtuzumab in patients with RRMS is durable over 10 years: follow-up from the CAMMS223 study. Poster session presented at European Committee for Treatment and Research in Multiple Sclerosis - ECTRIMS; 2017 Oct 25-28; Paris.

Association of British Neurologist. Guidance on the prevention of Listeria infection after alemtuzumab treatment of multiple sclerosis; [cited 2018 Mar 20]. Available at: https://www.theabn.org/media/GuidanceonthepreventionofListeriainfectionafteralemtuzumabtreatmentofmultiplesclerosis.pdf

10.1128/microbiolspec.TNMI7-0032-2016

World Health Organization. Global Tuberculosis Report; 2017. [updated 2018 May 21; cited 2018 May 23]. Available from: http://apps.who.int/iris/bitstream/handle/10665/259366/9789241565516-eng.pdf;jsessionid=01CD2566D2B6AB2F70EB31FFCD4D18D0?sequence=1.http://www.who.int/about/

10.1002/art.11137

10.1016/j.cmi.2015.03.010

10.1097/TP.0b013e31816f60cf

10.1016/j.leukres.2007.06.010

10.1136/ard.2007.070789

10.1007/s00430-016-0482-x

10.1089/sur.2016.008

10.1097/01.md.0000141100.30871.39

10.1093/infdis/134.3.286

10.1128/CMR.7.2.213

10.1086/510388

Truong J, Ashurst JV Pneumonia, pneumocystis (carinii) jiroveci. StatPearls Publishing; 2018 [Cited 2018 Feb 23]. Available from: https://Www.Ncbi.Nlm.Nih.Gov/Books/NBK482370/

10.1128/CMR.00013-12

10.1038/nrmicro1621

10.1177/1753465810380102

10.1097/QAD.0b013e32833a3967

10.1111/j.1399-3062.2012.00740.x

10.1111/imj.12599

10.1080/14787210.2018.1438264

10.1182/blood.V104.11.4816.4816

10.1212/WNL.0000000000004354

Uppsala Monitoring Centre. VigiBase, the World Health Organization (WHO) international database of suspected adverse drug reactions. [cited 2018 Mar 28]. Available from: https://www.who-umc.org/vigibase/vigibase/

10.1212/WNL.0b013e3182a35215